Hikma Pharmaceuticals plc set for FTSE 100 re-entry and Inmarsat plc for ejection

Hikma Pharmaceuticals plc (LON:HIK) is expected to join the FTSE 100 (INDEXFTSE:UKX), with Inmarsat plc (LON:ISAT) set for the boot.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Hikma Pharmaceuticals (LSE: HIK) lost its place in the FTSE 100 in March, but is set to storm back into the top index when the FTSE committee announces the results of its latest quarterly review on Wednesday. Satellite operator Inmarsat (LSE: ISAT) is currently standing on the trap door for demotion to the FTSE 250, to make way for resurgent Hikma.

Yo-yo

Hikma made history in March 2015 as the first Jordanian company to enter the FTSE 100. However, after just one year, a hiccup with a transformative acquisition of Roxane, the US generic drugs unit of Boehringer Ingelheim, saw the shares weaken to the extent that Hikma dropped back into the FTSE 250.

Hikma had agreed to buy Roxane in a $2.65bn cash-and-shares deal, but in February announced revised terms, which reduced the $1.18bn upfront cash component by about half “following the receipt of new information on Roxane’s financial performance in 2015”. As you might expect, such a revelation went down like a lead balloon.

However, Hikma had no sooner been demoted to the FTSE 250 than the shares began to charge north again. Investors seemed to reappraise the Roxane issue as not so serious after all, and to warm to the longer-term benefits of the acquisition for Hikma. Results in March and generally positive subsequent news flow have seen the shares climb 29% from a low of 1,704p to 2,203p, as I’m writing.

Valued at just shy of £5.3bn, Hikma will comfortably regain its place in the FTSE 100, barring a major collapse in its shares before the market closes on Tuesday.

Attractive rating

Analyst forecasts put Hikma on a current-year price-to-earnings (P/E) ratio of 26, with earnings being temporarily depressed as it digests Roxane. However, growth is expected to kick in rapidly thereafter, such that the 2017 P/E falls to 19. This looks an attractive rating for a growth company, and the value is underlined by a 2016/17 price-to-earnings growth (PEG) ratio of 0.5, which is well on the value side of the fair value marker of 1.

Canny investors did well to pick up the shares so cheaply in March, but even after the strong rise in the shares since, Hikma still appears to be good value for investors today.

Out of favour

Inmarsat’s shares have been heading lower all year. They ended 2015 at 1,137p and are currently trading 35% lower at 743p, valuing the company at £3.35bn. At the time of writing, Inmarsat is the detached weakling of the FTSE 100 herd and as things stand will be the company to make way for Hikma.

Challenging markets have been Inmarsat’s problem, and in Q1 results earlier this month the company revised down its revenue guidance for 2016. However, management left medium term guidance unchanged, and I tend to agree with those analysts who feel this could be vulnerable to a downgrade.

As it is, the consensus for next year’s earnings puts Inmarsat on a P/E of 19 — the same as Hikma. You can probably guess which of the two companies I prefer on this rating.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any shares mentioned. The Motley Fool UK has recommended Hikma Pharmaceuticals. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home
Investing Articles

Dividend deals! 2 passive income stocks that still look undervalued

Royston Wild explains why these FTSE 250 passive income stocks might STILL be too cheap to miss, despite theirrecent price…

Read more »

Middle-aged Caucasian woman deep in thought while looking out of the window
Investing Articles

Is BT Group one of the FTSE 100’s greatest value shares?

BT's share price looks like a bargain when you look at the P/E ratio and dividend yield. Is it one…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Investing Articles

The National Grid share price just plunged another 10%. Time to buy?

The National Grid share price is one of the FTSE 100's most stable, and nothing much happens to it? Well,…

Read more »

Young Black woman looking concerned while in front of her laptop
Investing Articles

Up 15% in 3 months, but I still won’t touch Vodafone shares with a bargepole

Harvey Jones has been shunning Vodafone shares for years. The FTSE 100 stock is finally showing signs of life, but…

Read more »

Growth Shares

This UK stock could be like buying Nvidia in 2021

Jon Smith thinks he's missed the boat with Nvidia shares, but flags up a UK stock that has some very…

Read more »

Businesswoman calculating finances in an office
Investing Articles

The FTSE 100’s Intertek delivers a bullish update — can the share price soar?

I’d describe Intertek as a quality business with a decent dividend income, but will the share price shoot the lights…

Read more »

Market Movers

Up another 10% yesterday, how high can the Nvidia share price go?

Jon Smith talks through the latest results but flags up why further gains could be harder to come by for…

Read more »

Investing For Beginners

Down 43% in a year, I think this value stock is primed for a comeback

Jon Smith flags up why a FTSE 250 share has fallen so much in the recent past, but explains why…

Read more »